American health regulators have taken a significant step toward making blood-sugar monitoring more accessible to families by clearing a wearable glucose tracking device for children as young as two years old — no doctor's prescription required. The move marks a new chapter for consumer health technology, extending a product category once limited to adults into the pediatric population.
The U.S. Food and Drug Administration announced on June 13, 2026, that it had granted marketing clearance to Dexcom Inc.'s Stelo Glucose Biosensor System for individuals aged two and above who do not rely on insulin to manage their condition. According to the FDA, this is the first over-the-counter continuous glucose monitor, or CGM, ever authorized for children in the United States.
The original Stelo clearance, issued in March 2024, had already been a landmark event — making Stelo the very first non-prescription CGM ever authorized in the U.S., at that time limited to adults 18 years and older. The latest decision now formally brings the technology within reach of families with young children.
Who the Device Is Intended For
The FDA specified that the pediatric clearance covers two groups of children: those managing diabetes through oral medication rather than insulin, and those without a formal diabetes diagnosis whose families want to understand how diet, physical activity, and daily habits influence blood sugar levels. The agency was clear that the Stelo system is not meant for insulin-dependent users.
The FDA framed the authorization as a direct public health response to growing rates of prediabetes among American children. Millions of young people in the United States face heightened risk of progressing to Type 2 diabetes, the agency said in its announcement, and early access to real-time glucose data could help build what regulators described as "glycemic awareness" — an understanding of how the body reacts to food, exercise, and other lifestyle factors.
The FDA said such awareness, developed early, could support healthier long-term outcomes for children and their families.
FDA Leadership Emphasizes Pediatric Health Access
Dr. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, issued a statement underscoring the agency's commitment to expanding health tools for younger patients. Dr. Tarver stated that children deserve access to the best tools available to manage their health, and described the clearance as reflecting the agency's dedication to "fostering innovation for pediatric patients and supporting the safe and effective use of medical devices where children live, learn, and play."
The FDA positioned the decision as part of a broader regulatory push to bring consumer-grade health monitoring to groups that were previously underserved by over-the-counter medical devices — a shift that has been building across several product categories in recent years.
How Stelo Works in Practice
The Stelo system functions through a small wearable sensor applied directly to the skin. Once in place, it continuously measures glucose levels derived from interstitial fluid — the fluid found just beneath the skin's surface — rather than requiring blood draws through finger-prick testing. The sensor pairs with a compatible smartphone application that records, analyzes, and displays glucose readings in near real time.
According to the FDA, the app can be installed on a parent's or caregiver's phone, enabling remote monitoring of a child's glucose trends throughout the day and night. Readings are updated every 15 minutes, giving caregivers a continuous picture of blood sugar patterns.
Each Stelo sensor is rated for up to 15 days of use before needing to be replaced. However, the FDA noted that actual wear duration may be shorter for children than for adults, owing to both physiological differences and the behavioral realities of pediatric users — a factor the agency said was taken into account during the review process.
Real-World Data Played a Key Role in Authorization
The FDA said the pediatric authorization was supported by a combination of data sources. According to the agency's announcement, Dexcom and the FDA combined earlier clinical study data drawn from both children and adult populations with real-world evidence on integrated CGM use across both groups. This blended methodology was used to assess how the device would perform across the full 15-day wear period in pediatric users.
The FDA said this approach — merging prospective clinical trial findings with real-world performance data — was sufficient to demonstrate the device's safety and effectiveness for children across the intended use population. Regulators have increasingly applied this type of combined data methodology to device authorizations, particularly in cases where conducting large-scale pediatric trials poses logistical or ethical difficulties.
Important Safety Cautions for Pediatric Users
The FDA attached a number of conditions and cautions to the pediatric clearance. The agency specified that for children, the Stelo device must be used under the continuous supervision of an adult caregiver at all times.
The Stelo system does not include alerts for hypoglycemia — dangerously low blood sugar — and is therefore not suitable for individuals who experience problematic low-glucose events. The FDA also stated that the device is not intended for people undergoing dialysis, and that individuals with a history of disordered eating or eating disorders should consult a healthcare provider before using it.
Participants in earlier clinical studies associated with the Stelo sensor reported mild adverse events at the application site, including local skin irritation, minor infection, and pain or discomfort, according to the FDA's announcement.
The agency stressed that Stelo readings are intended to serve as a supplementary health tool, and that users and caregivers should consult a licensed healthcare provider before making any changes to medication or treatment based on the device's data. The FDA was explicit that Stelo should not be used as a standalone guide for clinical decision-making.
Dexcom Expands the Market It Helped Create
Dexcom's original 2024 Stelo authorization opened the U.S. to consumer-grade, non-prescription glucose monitoring for the first time — a move widely considered a milestone in the convergence of medical technology and consumer wellness. At that time, CGMs had historically been restricted to patients managing diabetes under physician supervision.
Since 2024, other manufacturers have entered the over-the-counter CGM space, according to industry reporting, intensifying competition in what has become a fast-growing consumer health segment. Dexcom has previously stated that the Stelo platform was designed specifically for non-insulin users and was built with a cash-pay pricing model, making it available to consumers without a prescription drug benefit.
Part of a Larger FDA Initiative on Home-Based Health Monitoring
The FDA said the pediatric Stelo clearance is aligned with its Home as a Health Care Hub Initiative — a regulatory program aimed at advancing patient-centered medical devices that can be integrated into everyday life outside clinical settings. According to the agency, the initiative reflects an ongoing policy shift toward enabling more health monitoring and management to take place in the home, reducing the need for clinic-based testing for conditions that can be tracked using wearable technology.
With the extension of Stelo's clearance to children, the over-the-counter CGM market now formally encompasses pediatric users — a development the FDA described as meeting families where they are. The agency reiterated, however, that data from the device should be interpreted and acted upon in partnership with medical professionals, not independently used to drive treatment decisions.
The Stelo Glucose Biosensor System for children aged two and older is now authorized for marketing in the United States as of the date of the FDA's June 13, 2026 announcement.
Source: Originally reported by MedPage Today / FDA announcement